Letter to the Editor: The Role of Skin Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity
Author:
Philip R. Cohen
Philip R. CohenDepartment of Dermatology, University of California, Davis Medical Center, Sacramento, California; and Touro University California College of Osteopathic Medicine, Vallejo, California
FecherLA, BishuS, FontanaRJ, et al.The role of tissue biopsy in the management of immune checkpoint inhibitor toxicity. J Natl Compr Canc Netw2022;20:417–425.
FecherLA, BishuS, FontanaRJ, The role of tissue biopsy in the management of immune checkpoint inhibitor toxicity. J Natl Compr Canc Netw 2022;20:417–425.3539076310.6004/jnccn.2022.7011)| false
ParkBC, JungS, ChenST, et al.Challenging dermatologic considerations associated with immune checkpoint inhibitors. Am J Clin Dermatol. Published online June 16, 2022. doi: 10.1007/s40257-022-00706-y
EllisSR, VierraAT, MillsopJW, et al.Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol2020;83:1130–1143.
MuntyanuA, NetchiporoukE, GersteinW, et al.Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg2021;25:59–76.